The authors tested alectinib on a panel of NB cell lines, including CLB-BAR (MYCN/ALK-amplified), CLB-GE (MYCN/ALK-amplified and ALK-F1174V), CLB-PE (MYCN-amplified), and IMR-32 (MYCN-amplified), using crizotinib as a positive control. Here, ALK is linked to neuroblastoma.